| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/JBMR.1951 |
| P698 | PubMed publication ID | 23559035 |
| P50 | author | Adriano Angelucci | Q37376552 |
| P2093 | author name string | Nadia Rucci | |
| Anna Teti | |||
| Dick Heinegård | |||
| Luca Ventura | |||
| Maurizio Muraca | |||
| Barbara Peruzzi | |||
| Mattia Capulli | |||
| Viveka Tillgren | |||
| P2860 | cites work | The Primary Structure of a Basic Leucine-rich Repeat Protein, PRELP, Found in Connective Tissues | Q24315698 |
| The leucine-rich repeat protein PRELP binds perlecan and collagens and may function as a basement membrane anchor | Q28201679 | ||
| The amino-terminal part of PRELP binds to heparin and heparan sulfate | Q28573289 | ||
| The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF-kappaB inhibitor that impairs osteoclastogenesis | Q30481368 | ||
| Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. | Q34001564 | ||
| Clinical features of metastatic bone disease and risk of skeletal morbidity | Q34576366 | ||
| Metastasis and bone loss: advancing treatment and prevention. | Q34617837 | ||
| A systematic review of osteoporosis health beliefs in adult men and women | Q35219315 | ||
| Bone disease in pediatric rheumatologic disorders | Q35624611 | ||
| PRELP protein inhibits the formation of the complement membrane attack complex | Q35868224 | ||
| Clinical development of anti-RANKL therapy | Q35901092 | ||
| Risks and benefits of bisphosphonates | Q36696538 | ||
| Cancer to bone: a fatal attraction | Q36884628 | ||
| Consensus and controversy regarding osteoporosis in the pediatric population | Q36943010 | ||
| Cancer treatment-induced bone loss | Q36992803 | ||
| Denosumab in osteoporosis and oncology | Q37557994 | ||
| Therapeutic approach of primary bone tumours by bisphosphonates. | Q37781075 | ||
| The use of bisphosphonates in cancer treatment | Q37800183 | ||
| Clinical practice. Glucocorticoid-induced bone disease | Q37898140 | ||
| Bisphosphonate-induced osteopetrosis | Q44532555 | ||
| Early protective effect of total hypoxic preconditioning on rats against systemic injury from hemorrhagic shock and resuscitation | Q47744099 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 1912-1924 | |
| P577 | publication date | 2013-09-01 | |
| P1433 | published in | Journal of Bone and Mineral Research | Q15750941 |
| P1476 | title | Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss | |
| P478 | volume | 28 |
| Q30828525 | Murine models of breast cancer bone metastasis |
| Q38643835 | Non-conventional role of haemoglobin beta in breast malignancy. |
| Q49891124 | Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis |
| Q21710680 | Proteoglycan form and function: A comprehensive nomenclature of proteoglycans |
| Q52584355 | Regulation of breast cancer induced bone disease by cancer-specific IKKβ. |
| Q48293049 | TRAF2 in osteotropic breast cancer cells enhances skeletal tumour growth and promotes osteolysis |
| Q36192960 | The small leucine-rich repeat proteoglycans in tissue repair and atherosclerosis |
Search more.